LOS ANGELES, March 4, 2015 Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced today that it  has expanded its July, 2014 non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB: TRGM) ("Targeted Medical").  The agreement involves two products in Tauriga's current natural wellness line that Tauriga has reformulated and relabeled as dietary supplements from Targeted Medical's medical food formulations: ClearNaze, a natural decongestant without stimulant or drowsiness effects, and Satietiva, an amino acid-based appetite suppressant.  Tauriga and Targeted Medical expanded the original July, 2014 non-exclusive licensing agreement to allow Tauriga to market and sell directly to all consumers, not just to those with an interest in the effects of medicinal cannabis.

Tauriga Chairman and CEO Dr. Stella M. Sung states, "We are thrilled to commercialize ClearNaze and Satietiva, along with Tauriga's proprietary formulations, to a broader population because we believe that all of our natural wellness products produce functional improvement independent of the etiology or cause of the health challenge."

Targeted Medical CEO Kim Giffoni adds, "The expanded relationship is beneficial for both companies.  Tauriga's success in generating revenues for ClearNaze and Satietiva will result in royalty revenue for Targeted Medical, and our efforts are complementary and synergistic."

Tauriga's recently launched natural wellness product line currently consists of six products.  Two of these products contain cannabidiol (CBD) oil extracted from non-GMO industrial hemp as their key ingredient: CannaCaviar, the Company's cannabidiol (CBD) soft gels; and TopiCanna, Tauriga's proprietary topical medicinal cannabis cream.  Both TopiCanna and CannaCaviar are designed to provide potential natural wellness and healing properties without psychoactive effects.  Tauriga has two non-cannabis containing natural wellness dietary supplements in addition to ClearNaze and Satietiva:  IndiCalm, an anxiolytic that does not induce cognitive impairment, and MendOCan, a highly pure, potent and palatable Omega 3 supplement.  For more information on Tauriga's natural wellness product line, please visit www.taurigastore.com.

Lawrence A. May, M.D., Tauriga's Chief Medical Officer and previously head of medical affairs at Herbalife, states, "I have worked with medical foods for over ten years, and I am enthusiastic about applying the technology for generating neurotransmitters to create dietary supplements that improve function and enhance health.  Until now, this technology was only available under physician supervision.  Tauriga's products provide the consumer direct access to the technology for the first time."

About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology.  The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms.  Please visit the Company's corporate website at www.tauriga.com and the Company's e-commerce website at www.taurigastore.com.

NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Food and Drug Administration Disclaimer:  None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration.  Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tauriga-sciences-inc-expands-agreement-with-targeted-medical-pharma-inc-300045217.html

SOURCE Tauriga Sciences, Inc.